Document is current
Any future updates will be listed below
-
Authors
Chaki, Moumita
Benrashid, Mona
Puri, Subir
Sivakumar, Smruthy
Sokol, Ethan S.
Briceno, Josefa M.
Neil Vasan,
- License Information
-
More Information
Article History
Received: 10 March 2025
Accepted: 22 May 2025
First Online: 1 July 2025
Declarations
:
: Approval for this study, including a waiver of informed consent and a Health Insurance Portability and Accountability Act (HIPAA) Waiver of Authorization, was obtained from the Western Institutional Review Board (protocol number 20152817).
: Not applicable.
: MC, MB, SP and JMB declare employment and stock/other ownership interests with AstraZeneca. SS and ESS declare employment with Foundation Medicine and stock/other ownership interests with Roche. NV declares leadership of Heligenics; stock/other ownership interests with Heligenics and Reactive Biosciences, honoraria from General Dynamics Information Technology (GDIT) and Guidepoint Global; consultancy/advisory role with Avenzo Therapeutics, Gilead Sciences, Pfizer, Reactive Biosciences, Sanofi and Scorpion Therapeutics; research funding and travel/accommodation/expenses from Gilead Sciences; a patent as follows Vasan N, Baselga J. U.S. Patent Number WO2020041684A1: “Biomarkers for Determining Responsiveness of a Cancer to PI3K Inhibitors,” Patent granted February 27, 2020.
